Search tips
Search criteria 


Logo of brjgenpracThe British Journal of General Practice
Br J Gen Pract. 1996 March; 46(404): 145–148.
PMCID: PMC1239570

Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial.


BACKGROUND: Nicotine replacement therapy is effective in helping people to give up smoking. The three forms now available--transdermal patches, chewing gum and nasal spray--deliver nicotine at different rates and to different levels. Therefore, it might be expected that smokers with different characteristics, and at different levels of nicotine dependence, will be helped more by one or other method. AIM: The aim of the study was to examine whether the effectiveness of transdermal patches is related to nicotine dependence or to other smoker characteristics and to investigate factors predicting smoking cessation using patches. METHOD: Data from a randomized, double-blind, placebo-controlled trial of nicotine transdermal patches were analysed retrospectively. The trial, conducted in 1990-1992, involved 1686 patients recruited from 19 general practices in Oxfordshire. The main outcome measure was continuous smoking cessation from 8 to 52 weeks after the start of patch use, biochemically validated at 12, 24 and 52 weeks. The effectiveness of the patches was measured by the relative odds of sustained cessation using nicotine patches compared with placebo patches. RESULTS: Nicotine transdermal patches were more effective in smokers with moderate nicotine dependence [odds ratio (OR) 1.94; 95% confidence interval (CI) 1.24-3.04] than in mildly or highly dependent smokers (OR 0.98; 95% CI 0.58-1.65) (difference in ORs P < 0.05) and more effective in those aged 24-49 years (OR 1.89; 95% CI 1.24-2.87) than in older smokers aged 50-65 years (OR 0.88; 95% CI 0.49-1.59) (difference in ORs P < 0.05). Abstinence from smoking in the first week of the trial was the strongest predictor of sustained cessation and was more common among smokers using nicotine patches than those using placebo patches (33% of 842 compared with 22% of 844; P < 0.001). Of first-week abstainers, 25 and 28% of 277 and 182 in the nicotine and placebo groups, respectively, achieved sustained cessation compared with 4% of 565 and 2% of 662 first-week smokers. CONCLUSION: Nicotine transdermal patches were most effective for smokers with moderate nicotine dependence and for younger smokers. Early abstinence from smoking was the strongest predictor of sustained cessation. A week's trial of the patch proceeding to longer term use if abstinence is achieved may be an effective policy.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (928K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Richmond RL, Kehoe LA, Webster IW. Multivariate models for predicting abstention following intervention to stop smoking by general practitioners. Addiction. 1993 Aug;88(8):1127–1135. [PubMed]
  • Sanders D, Peveler R, Mant D, Fowler G. Predictors of successful smoking cessation following advice from nurses in general practice. Addiction. 1993 Dec;88(12):1699–1705. [PubMed]
  • Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ. 1994 Oct 1;309(6958):842–846. [PMC free article] [PubMed]
  • Hatziandreu EJ, Pierce JP, Lefkopoulou M, Fiore MC, Mills SL, Novotny TE, Giovino GA, Davis RM. Quitting smoking in the United States in 1986. J Natl Cancer Inst. 1990 Sep 5;82(17):1402–1406. [PubMed]
  • McWhorter WP, Boyd GM, Mattson ME. Predictors of quitting smoking: the NHANES I followup experience. J Clin Epidemiol. 1990;43(12):1399–1405. [PubMed]
  • Coambs RB, Li S, Kozlowski LT. Age interacts with heaviness of smoking in predicting success in cessation of smoking. Am J Epidemiol. 1992 Feb 1;135(3):240–246. [PubMed]
  • Lundberg O, Rosén B, Rosén M. Who stopped smoking? Results from a panel survey of living conditions in Sweden. Soc Sci Med. 1991;32(5):619–622. [PubMed]
  • Cohen S, Lichtenstein E, Prochaska JO, Rossi JS, Gritz ER, Carr CR, Orleans CT, Schoenbach VJ, Biener L, Abrams D, et al. Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol. 1989 Nov;44(11):1355–1365. [PubMed]
  • Nørregaard J, Tønnesen P, Petersen L. Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med. 1993 Mar;22(2):261–271. [PubMed]
  • Lennox AS. Determinants of outcome in smoking cessation. Br J Gen Pract. 1992 Jun;42(359):247–252. [PMC free article] [PubMed]
  • Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994 Jun 22;271(24):1940–1947. [PubMed]
  • Silagy C, Mant D, Fowler G, Lodge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994 Jan 15;343(8890):139–142. [PubMed]
  • Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ. 1994 Jan 1;308(6920):21–26. [PMC free article] [PubMed]
  • Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, Feyerabend C. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet. 1992 Aug 8;340(8815):324–329. [PubMed]
  • Gourlay SG, McNeil JJ. Antismoking products. Med J Aust. 1990 Dec 3;153(11-12):699–707. [PubMed]
  • Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. JAMA. 1992 Nov 18;268(19):2687–2694. [PubMed]
  • Russell MA, Raw M, Jarvis MJ. Clinical use of nicotine chewing-gum. Br Med J. 1980 Jun 28;280(6231):1599–1602. [PMC free article] [PubMed]
  • Abelin T, Buehler A, Müller P, Vesanen K, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet. 1989 Jan 7;1(8628):7–10. [PubMed]
  • Jarvis MJ, Russell MA, Saloojee Y. Expired air carbon monoxide: a simple breath test of tobacco smoke intake. Br Med J. 1980 Aug 16;281(6238):484–485. [PMC free article] [PubMed]
  • Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA. 1994 Feb 23;271(8):589–594. [PubMed]
  • Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, Wiseman D. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction. 1995 Jan;90(1):31–42. [PubMed]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners